Gilead Sciences Rating Reiterated by TheStreet (GILD)
Gilead Sciences (NASDAQ:GILD)‘s stock had its “buy” rating reiterated by analysts at TheStreet in a research report issued to clients and investors on Monday, Analyst Ratings.Net reports.
The analysts wrote, “Gilead (GILD) has been reiterated by TheStreet Ratings as a buy with a ratings score of A. The company’s strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow.”
Gilead Sciences (NASDAQ:GILD) traded down 0.56% on Monday, hitting $62.341. 2,582,736 shares of the company’s stock traded hands. Gilead Sciences has a 52 week low of $32.07 and a 52 week high of $64.74. The stock’s 50-day moving average is $61.99 and its 200-day moving average is $56.13. The company has a market cap of $95.421 billion and a P/E ratio of 35.08.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, July 25th. The company reported $0.50 EPS for the quarter, meeting the Thomson Reuters consensus estimate of $0.50. The company had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.66 billion. During the same quarter in the prior year, the company posted $0.99 earnings per share. The company’s quarterly revenue was up 14.5% on a year-over-year basis. Analysts expect that Gilead Sciences will post $1.96 EPS for the current fiscal year.
A number of other firms have also recently commented on GILD. Analysts at Zacks downgraded shares of Gilead Sciences from an “outperform” rating to a “neutral” rating in a research note to investors on Wednesday, September 25th. They now have a $66.00 price target on the stock. Separately, analysts at Ameriprise Financial initiated coverage on shares of Gilead Sciences in a research note to investors on Thursday, September 19th. They set a “buy” rating on the stock. Six equities research analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $67.57.
Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.